SLC5A2 and type 2 diabetes mellitus: Empagliflozin is a drug primarily used to lower blood glucose in type II diabetes patients by inhibiting the sodium–glucose cotransporter-2 (SGLT-2) found in the proximal tubules in the kidneys.